SCHEMBL941785

SCHEMBL941785

CC1(CS(=O)(=O)c2ccc(-c3ccccc3)cc2)NC(=O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.44
MMP2 P08253 6/20 0.43
MMP14 P50281 3/20 0.43
MMP7 P09237 2/20 0.43
MMP9 P14780 4/20 0.42
MMP3 P08254 2/20 0.42
LIPG Q9Y5X9 2/20 0.41
PTGS2 P35354 1/20 0.40
MMP13 P45452 2/20 0.40
MMP8 P22894 1/20 0.40
LIPC P11150 1/20 0.39
MMP1 P03956 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
ADAM17 P78536 1/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12378667 0.85 CA12 (0.42) ALDH1A1MMP2MMP14MMP13ADAM17
SCHEMBL941823 0.84 MMP13 (0.46) ALDH1A1MMP2MMP14MMP7MMP9
SCHEMBL12418579 0.82 MMP13 (0.38) ALDH1A1MMP14MMP13
SCHEMBL12378832 0.82 PLCG1 (0.44) ALDH1A1MMP2MMP14MMP13ADAMTS5
SCHEMBL6210220 0.82 MMP13 (0.51) MMP14PTGS2MMP13ADAMTS5
SCHEMBL12416707 0.80 ADAM17 (0.57) ALDH1A1MMP2MMP14MMP7MMP9
SCHEMBL6841100 0.74 ALDH1A1 (0.46) ALDH1A1MMP2MMP9MMP3LIPG
SCHEMBL14085484 0.73 ALDH1A1 (0.46) ALDH1A1MMP2MMP14MMP9MMP3
SCHEMBL6211424 0.73 ADAM17 (0.53) MMP14MMP13ADAM17
SCHEMBL12416702 0.72 ALDH1A1 (0.48) ALDH1A1MMP2MMP14MMP9MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110003853-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2011-01-06 US disclosed
US-7754750-B2 a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) ASTRAZENECA AB (SE) 2010-07-13 US disclosed
US-7625934-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2009-12-01 US disclosed
US-20080306065-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-12-11 US disclosed
US-7427631-B2 especially as inhibitors of MMP12 ASTRAZENECA AB (SE) 2008-09-23 US disclosed
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS SCHERING CORPORATION 2008-09-18 US disclosed
US-20080171882-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-07-17 US disclosed
EP-1370556-B1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2006-07-19 EP disclosed
EP-1676846-A2 Hydantoin derivatives as MMP inhibitors AstraZeneca AB (SE) 2006-07-05 EP disclosed
US-20040127528-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003853-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 ALDH1A1 612/4885MMP2 15/4885MMP14 3/4885
US-20080226618-A1 HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS LPXN, HAX1, LCT ALDH1A1 1419/4885MMP2 1337/4885MMP14 1343/4885
US-20080306065-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 ALDH1A1 612/4885MMP2 15/4885MMP14 3/4885
US-20080171882-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP14 ALDH1A1 612/4885MMP2 15/4885MMP14 3/4885
US-20040127528-A1 Metalloproteinase inhibitors MMP9, MMP10, MMP3 ALDH1A1 573/4885MMP2 11/4885MMP14 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.